H. pylori infection causes gastritis, PUD, gastric cancer and mucosa-associated lymphoid tissue (MALT) lymphoma. Approximately 20% of infected individuals will develop PUD and less than 1% will develop gastric cancer. HP eradication markedly decreases ulcer recurrence. Assuming your patient tests positive for this organism, describe your therapeutic plan including possible medication options, patient and drug related factors used to make your selection, duration of therapy, monitoring, patient education and any potential follow up such as labs, testing or continued use for PPIs.

H. pylori infection causes gastritis, PUD, gastric cancer and mucosa-associated lymphoid tissue (MALT) lymphoma. Approximately 20% of infected individuals will develop PUD and less than 1% will develop gastric cancer. HP eradication markedly decreases ulcer recurrence. Assuming your patient tests positive for this organism, describe your therapeutic plan including possible medication options, patient and drug related factors used to make your selection, duration of therapy, monitoring, patient education and any potential follow up such as labs, testing or continued use for PPIs.

H. pylori  infection causes gastritis, PUD, gastric cancer and mucosa-associated lymphoid tissue (MALT) lymphoma. Approximately 20% of infected individuals will develop PUD and less than 1% will develop gastric cancer. HP eradication markedly decreases ulcer recurrence. Assuming your patient tests positive for this organism, describe your therapeutic plan including possible medication options, patient and drug related factors used to make your selection, duration of therapy, monitoring, patient education and any potential follow up such as labs, testing or continued use for PPIs.